Search research articles
Contact Us
Filters
Showing results (21-30 of 61) with videos related to
Page
of 7
Sort By:
International Journal of Clinical Oncology
|
October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Oncology
|
December 31, 2023
Pattern of Expression of MicroRNA in Patients with Radiation-Induced Bladder Injury
Ko Nakamura, Takaya Ohno, Teruo Inamoto, et al.
Journal of Cancer Research and Clinical Oncology
|
April 9, 2024
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
Yosuke Hirasawa, Takahiro Adachi, Takeshi Hashimoto, et al.
NPJ Precision Oncology
|
September 17, 2024
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma
Kazuki Nishimura, Kiyoshi Takahara, Kazumasa Komura, et al.
Cancer Diagnosis & Prognosis
|
May 11, 2023
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma
Teruo Inamoto, Ryo Sato, Yuto Matsushita, et al.
Urologic Oncology
|
March 29, 2022
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors
Wataru Fukuokaya, Takahiro Kimura, Kazumasa Komura, et al.
Oncogene
|
September 21, 2021
Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents
Kazumasa Komura, Teruo Inamoto, Takuya Tsujino, et al.
In Vivo (Athens, Greece)
|
January 2, 2023
Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer
Atsushi Ichihashi, Teruo Inamoto, Taizo Uchimoto, et al.
Urologic Oncology
|
March 29, 2022
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma
Taizo Uchimoto, Ko Nakamura, Kazumasa Komura, et al.
Biotechniques
|
June 28, 2025
Dual compartment utility of BRET-based biosensors for PPP2R5A/B56α, a cancer-associated B regulatory subunit of PP2A
Hirofumi Yamauchi, Atsuro Oishi, Masahiko Ajiro, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 61) with videos related to
Sort By:
Page
of 7
International Journal of Clinical Oncology
|
October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Oncology
|
December 31, 2023
Pattern of Expression of MicroRNA in Patients with Radiation-Induced Bladder Injury
Ko Nakamura, Takaya Ohno, Teruo Inamoto, et al.
Journal of Cancer Research and Clinical Oncology
|
April 9, 2024
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
Yosuke Hirasawa, Takahiro Adachi, Takeshi Hashimoto, et al.
NPJ Precision Oncology
|
September 17, 2024
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma
Kazuki Nishimura, Kiyoshi Takahara, Kazumasa Komura, et al.
Cancer Diagnosis & Prognosis
|
May 11, 2023
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma
Teruo Inamoto, Ryo Sato, Yuto Matsushita, et al.
Urologic Oncology
|
March 29, 2022
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors
Wataru Fukuokaya, Takahiro Kimura, Kazumasa Komura, et al.
Oncogene
|
September 21, 2021
Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents
Kazumasa Komura, Teruo Inamoto, Takuya Tsujino, et al.
In Vivo (Athens, Greece)
|
January 2, 2023
Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer
Atsushi Ichihashi, Teruo Inamoto, Taizo Uchimoto, et al.
Urologic Oncology
|
March 29, 2022
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma
Taizo Uchimoto, Ko Nakamura, Kazumasa Komura, et al.
Biotechniques
|
June 28, 2025
Dual compartment utility of BRET-based biosensors for PPP2R5A/B56α, a cancer-associated B regulatory subunit of PP2A
Hirofumi Yamauchi, Atsuro Oishi, Masahiko Ajiro, et al.
Page
of 7